Lupin has received final approval for its Bimatoprost Ophthalmic Solution, 0.03% from the United States Food and Drugs Administration (FDA) to market a generic version of Allergan Lumigan Ophthalmic Solution, 0.03%. Lupin Pharmaceuticals (LPI), the company's US subsidiary would commence marketing the product shortly.

Lupin's Bimatoprost Ophthalmic Solution, 0.03% is the AT rated generic equivalent of Lumigan Ophthalmic Solution, 0.03% and is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The product has more than USD 500 million sales in US, with only Apotex being the other player in the market. Thus the product can contribute well for company's US sales in FY2016. In FY2016, the company can easy garner sales of USD 50-80 million in sales for the company.
 
Lupin's Bimatoprost Ophthalmic Solution, 0.03% filing was made from its Indore facility which was audited in January, 2015. Two Lupin facilities, the Lupin Bioresearch Center, Pune (LBC) and its manufacturing facility at Pithampur, near Indore were audited by the US FDA in November, 2014 and January, 2015 respectively. Both the audits were completed successfully with LBC not receiving any observations and the Indore facility receiving six observations (483's). Since then, the Indore facility has received 1 ANDA approval and 2 site-transfer approvals.

Angel Broking maintains neutral rating on the stock. 

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.